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CONFLICT OF INTEREST IN THE PHARMACEUTICAL SECTOR: 
A GUIDE FOR PUBLIC MANAGEMENT 
Marc A. Rodwin1 
 
Abstract	
 
This article outlines the key kinds of conflicts of interest that exist in the 
pharmaceutical sectors and shows how they affect 12 areas related to the 
development, marketing, and distribution of pharmaceuticals.  It explains 
how these conflicts of interest can compromise good practice and 
policy.  Most importantly, it sets forth a step-by-step guide for managing 
such conflicts of interest in the public and private sectors.  
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I. WHAT ARE CONFLICTS OF INTEREST? 
The pharmaceutical sector plays a vital role in the promotion of 
individual health care and public health. However, the conflicts of interest 
in the pharmaceutical sector compromises the integrity of medical practice, 
appropriate prescribing, patient safety, and public health.2 It can also lead to 
governments, insurers, and patients paying more for medications. Increased 
costs mean increased social burden that imposes an unnecessary limit on 
global access to essential medicines. 
Conflicts of interest can compromise the integrity of key parts of the 
pharmaceutical sector. Policies that preclude, manage, or mitigate conflicts 
of interest promote the integrity of governmental decisions and decisions by 
medical professionals, who play strategic roles related to the use of 
medications. Public policies that promote transparency, like policies that 
target overt corruption are therefore aligned with conflicts of interest 
policies but distinct from them.3 This article describes conflicts of interest 
in the pharmaceutical sector and ways public policy can address them. 
The idea underlying conflicts of interest is simple: it is implicit in the 
principle that no individual can judge his or her own case because that 
would mix two incompatible roles, playing both the participant and the 
judge. A judge is supposed to be unbiased when deciding the outcome of a 
case. However, a judge cannot be neutral when he or she must decide a case 
that pits the judge—or member of the judge’s family—against another 
party. Similarly, a judge who has strong financial ties or a close friendship 
with one party in a court case is also likely to be biased in that party’s favor. 
Other governmental officials also exercise authority that affects the 
public. These public servants also have obligations to make decisions fairly, 
to fulfill their public mission impartially despite their personal interests. Yet 
administrators and public servants sometimes have personal interests that 
can bias their decisions. 
                                                
2 Marc A. Rodwin, Conflicts of Interest, Institutional Corruption, and Pharma: 
An Agenda for Reform, 40 J. OF L. MED. & ETHICS 511, 511-22 (2012). 
3 See generally Guitelle Baghdadi-Sabeti et al., Measuring Transparency in the 
Public Pharmaceutical Sector, WORLD HEALTH ORGANIZATION [WHO] (2009), 
http://apps.who.int/medicinedocs/documents/s16732e/s16732e.pdf; See generally 
Jillian C. Kohler et al., Corruption in the Pharmaceutical Sector: Diagnosing the 
Challenges, TRANSPARENCY INTERNATIONAL UK (2016), 
https://www.transparency.cz/wp-content/uploads/Corruption-in-the-Pharma-
Sector.pdf. 
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Physicians, pharmacists, and other professionals working in both the 
public and the private sectors also have obligations to serve the interests of 
designated parties or to perform certain public functions. Yet these 
professionals sometimes have a personal stake in matters that can cause 
them to favor their own interests over the interests of their patients, clients, 
or other parties they are supposed to serve. 
A. Definitions 
This article uses as its starting point the traditional legal definition 
used by the Organization for Economic and Cooperative Development 
(OECD), which focuses on conflicts of interest of public sector actors.4 The 
OECD says that, “‘a conflict of interest’ involves a conflict between the 
public duty and private interests of a public official, in which the public 
official has private-capacity interests, which could improperly influence the 
performance of their official duties and responsibilities.”5 
Bear in mind that conflicts of interest do not constitute a breach of 
duty. Although law or ethics may require individuals to not enter into 
conflict-of-interest situations, this is only a measure to prevent acts 
considered wrong in themselves. Conflicts of interest can influence action, 
but they are not acts and do not constitute a breach of trust. Furthermore, 
conflicts of interest are distinct from conflicting interests. Multiple interests 
often pull people in different directions. But unless such conflicting 
interests compromise an individual or party’s obligations, no conflict of 
interest exists. 
Conflicts of interest constitute a problem for two reasons: (1) they 
compromise an actor’s loyalty to her mission or the parties they are 
supposed to serve, and (2) they compromise the actor’s independent 
                                                
4 The Organization for Economic Co-operation and Development [OECD] 
uses the traditional legal definition. Some writers have attempted to redefine 
conflicts of interest with confusing results. See Marc A. Rodwin, Attempts to 
Redefine Conflicts of Interest, ACCOUNTABILITY IN RESEARCH 67, 67-78 (2018).  
5 OECD, Managing Conflict of Interest in the Public Service: OECD 
Guidelines and Country Experiences (2004), 
http://www.oecd.org/gov/ethics/48994419.pdf [hereinafter Country Experiences]; 
See also OECD, Managing Conflicts of Interest in the Public Sector: A Toolkit 
(2005), https://www.oecd.org/gov/ethics/49107986.pdf [hereinafter A toolkit] See 
also, MARC A. RODWIN, MEDICINE, MONEY AND MORALS: PHYSICIANS’ 
CONFLICTS OF INTEREST, 629-34 (1993); MARC A. RODWIN, CONFLICTS OF 
INTEREST AND THE FUTURE OF MEDICINE: THE UNITED STATES, FRANCE, AND 
JAPAN 15-16 (2011) [hereinafter The Future of Medicine].  
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judgment.6 Consequently, conflicts of interest increase the risk that 
individuals will not perform their duties as they should, or even cause them 
to breach their obligations. The least serious form of breach could be 
professional neglect: a compromised public employee might not perform at 
his or her customary high level of competence, diligence, or effectiveness. 
In its most egregious form, public servants and publicly employed 
professionals may knowingly exploit their position. Extreme disloyalty 
obviously presents more dramatic danger but is easier to identify. Situations 
that compromise independence, loyalty, or judgment more subtly or even 
unintentionally, occur more frequently but are harder to recognize. 
B. Some Distinctions 
Individual Conflicts of Interest 
Two main kinds of conflicts of interest exist: Financial and Divided Loyalty 
Conflicts 
Financial conflicts of interest arise when an individual has financial 
interests that can affect decisions he makes when performing his duties. 
These personal interests might present a strong incentive to ignore public 
duty and bias the official towards his or her own wallet, or the wallet of 
friends and family. Divided loyalty conflicts of interest arise when an 
individual’s loyalty is split between two parties with differing interests. An 
individual can engage in multiple activities that are acceptable when 
considered individually, yet often conflict when one individual performs 
them simultaneously. 
Potential and Apparent Conflicts 
The OECD uses the term “potential conflict of interest” for 
situations in which an official would have a conflict of interest if there were 
certain changes in their official work activities or in the individual’s 
activities outside of work such that the individual would then have a 
conflict between his work duties and personal interests.7 
The OECD reserves the term apparent conflict of interest for 
situations where it appears to many observers that a public official’s private 
interests could improperly influence their performance of professional 
duties, but where in fact there is no conflict because arrangements have 
                                                
6 MARC A. RODWIN, MEDICINE, MONEY, AND MORALS: PHYSICIANS’ 
CONFLICTS OF INTEREST 8-11 (1993); Rodwin, supra note 4, at 15-17.  
 
7 Country Experiences, supra note 3, at 58. 
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been made for the official to stand aside from all decision-making related to 
the activities in which the official would have a conflict.8 
For example, a public servant with an ownership interest in a private 
firm has a potential conflict of interest because the public servant has a 
private interest in the success of the firm that might conflict with the 
official’s exercise of her duties. However, if the public servant works in the 
transportation ministry and is an investor in a pharmaceutical firm or 
pharmacy, the public servant’s work is unlikely to affect the private firm or 
vice versa. If the public servant is reassigned to work in a bureau that 
approves the marketing of medicines or that regulates pharmacies, then the 
public servant’s financial interest will likely create an actual conflict of 
interest. The test is whether the performance of public duties by the public 
official can influence decisions in favor of the business in which the official 
has financial ties. 
Similarly, an individual who works in a pharmaceutical affairs 
bureau, and whose sister manages a pharmaceutical firm, has an apparent 
conflict of interest because it appears that the official’s duties will conflict 
with his interest in helping his sister’s firm. It remains an apparent conflict 
rather than an actual conflict of interest if arrangements have been made so 
that the official will not participate in any pharmaceutical bureau decisions 
that affect the firm in which the official’s sister is a manager. 
Conflicts of Interest of Professionals in the Private Sector  
Professionals working in the private sector can also have conflicts 
of interest when they serve on government commissions or advisory boards 
or offer expert advice to public officials. Under these circumstances, these 
professionals perform public functions and therefore are expected to act as 
if they were performing their work as public employees. Yet these 
professionals might have financial interests affected by the outcome of their 
public decision. Consequently, they might be in a situation where they can 
perform their public sector functions in ways that promote their private 
interests. 
Furthermore, there can also be conflicts of interest for professionals 
that work in private practice even when they do not perform any work for 
the public sector. For example, physicians and pharmacists have 
professional obligations to act in the best interests of their patients and to 
comply with professional norms. Since these professionals earn their living 
by performing their professional work, their personal financial interests can 
create an incentive for them to write prescriptions, offer advice, or generally 
                                                
8 Id. 
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make decisions that promote their personal financial interests over the 
interests of their patients. 
Institutional Conflicts of Interest  
An institutional conflict of interest exists when an organization 
performs two or more roles that can conflict.9 This typically occurs when 
the institution has financial interests that can cut against an institutional 
mission or activity. Some writers also hold that when an institution’s senior 
official has financial interests that can affect institutional policies, that 
situation also creates an institutional conflict of interest.10 However, the 
financial interests of senior officials in an organization can also be analyzed 
as reflecting their individual conflicts of interest. 
In the United States, many private not-for-profit universities and 
hospitals have joint ventures with for-profit firms to conduct research and 
commercialize products derived from the research.11 The university or 
hospital will share profits or royalties from pharmaceuticals or other 
products derived from the research. Meanwhile, these universities have a 
mission of promoting inquiry and public access to knowledge and 
obligations to oversee the integrity of university researchers and to monitor 
the financial conflicts of interest of researchers. In this situation, the 
university has a financial interest in the outcome of the research that can 
conflict with its mission as an educational and research institution.12 For 
example, if an institution conducts research to evaluate a pharmaceutical 
product while earning income from the product’s sale, those two activities 
create an institutional conflict of interest. 
 
 
                                                
9 Id. at 66. 
10 See generally Association of American Universities, Report on Individual 
and Institutional Financial Conflict of Interest (2001), 
http://ccnmtl.columbia.edu/projects/rcr/rcr_conflicts/misc/Ref/AAU_CoI.pdf; 
Bernard Lo & Marilyn J. Field, Conflict of Interest in Medical Research, 
Education, and Practice, INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMICS 
[IOM] (2009), http://www.kumc.edu/Documents/coi/TOC.pdf.  
11 SHELDON KRIMSKY, SCIENCE IN THE PRIVATE INTEREST: HAS THE LURE OF 
PROFITS CORRUPTED BIOMEDICAL RESEARCH? 27-56 (2004); See Mark Barnes & 
Patrik S. Florencio, Financial Conflicts of Interest in Human Subjects Research: 
The Problem of Institutional Conflicts, 30 J. L. MED. & ETHICS 390, 390 (2002). 
12 Ezekiel J. Emanuel & Daniel Steiner, Institutional Conflict of Interest, 332 
NEW ENG. J. MED. 262, 262 (1995). 
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II. TWELVE AREAS OF CONFLICTS OF INTEREST 
RELATED TO PHARMACEUTICALS  
Conflicts of interest compromise good pharmaceutical policy in 12 
related areas. These areas occur in multiple points in the medication life 
cycles. These include, at the beginning of the medication life cycle, research 
on safety and effectiveness required prior to marketing the drugs. At the end 
of the medication life cycle they include monitoring drug safety after drugs 
are on the market. In between there are 10 additional points where decisions 
about medications present opportunities for conflicts of interest. 
Exhibit A, below, displays these twelve areas roughly in the chronological 
order. 
 
Exhibit A 
Twelve Areas of Conflicts of Interest in the Medication Life Cycle 		
1) 
Safety/ 
Effectiveness 
Research 
 
2) 
Medical 
Publication 
 
3) 
Registration 
/Marketing 
authorizatio
n) 
4) 
Reimbursement 
& Pricing 
5) 
Mfg. & 
Distribution 
6) 
Procurement 
      
7) 
Standard 
Treatment 
Guidelines 
8) 
Formulary 
Selection 
9) 
Continuing 
Education 
10) 
Prescribing 
11) 
Dispensing 
12) 
Post-
Marketing 
Drug Safety 
 
 
Research to Test Medicines for Safety and Effectiveness 
Governmental authorities require that pharmaceutical products be tested 
for safety and effectiveness before they authorize their sale. Typically, 
governments require that manufacturers submit evidence of safety and 
effectiveness derived from clinical trials. The results of clinical research to 
test medicines can therefore influence whether a medicine can be sold, for 
what purposes it can be marketed, the claims that manufacturers can make 
when marketing the medicine, and the warnings of health risks that 
manufacturers must provide. The information from clinical research also 
often affects the choices made by authorities that regulate medicine prices, 
the decisions of purchasers and prescribers, the medicine formularies 
developed by hospitals and health systems, and choices that patients make. 
8 Marc A. Rodwin. Conflict of Interest in the Pharmaceutical Sector  
Many pharmaceutical researchers have conflicts of interest, 
including the individuals who design clinical trials or carry out the research 
or interpret and report the data. These researchers are supposed to provide 
objective evaluation of a pharmaceutical product, but pharmaceutical firms 
that wish to commercialize a medicine are often the ones who pay the 
researchers to conduct the research. Other times, pharmaceutical firms 
employ these researchers as consultants or offer them grants and gifts. 
These researchers might conduct their work in a way that promotes results 
favoring the interest of the pharmaceutical firms with which they have 
financial ties. 
 
Medical Publication 
Medical journals publish articles reporting on clinical trials that evaluate 
pharmaceutical products. These articles affect the decisions of physicians, 
pharmacists, and policymakers. The authors of medical journal articles can 
have financial ties with pharmaceutical firms and these ties can bias their 
publications. Medical journal peer reviewers can also have financial ties 
with pharmaceutical firms, and these ties can bias their evaluation. For 
example, both authors of journal articles as well as peer reviewers might 
depend on pharmaceutical firms for employment, consulting income or 
grants and gifts. In addition, medical journals often depend on revenue from 
pharmaceutical firms’ advertising for and purchasing of article reprints. 
 
Registration of Pharmaceuticals (authorization to market, approved uses, 
labeling) 
National authorities typically regulate the marketing of medicines by 
setting rules for registration and sale of pharmaceutical products. These 
rules are intended to protect the public. If the public officials working in 
these agencies have financial interests in the pharmaceutical firms they 
regulate, then these public officials have conflicts of interest that can bias 
their decisions regarding the sale of pharmaceuticals. 
Frequently, public authorities ask experts in the private sector to 
advise them regarding the registration of pharmaceutical products. When 
these experts earn income from pharmaceutical firms, then in turn offer 
advice to public authorities on sale of the pharmaceutical firm’s products, 
the experts have a conflict of interest. 
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Regulation of Reimbursement and Pricing 
Many nations regulate the price of pharmaceutical products. If 
decision makers have financial ties with pharmaceutical firms then conflicts 
of interest are created that can affect governmental pricing decisions. 
 
Pharmaceutical Manufacturing, Distribution, and Oversight of Pharmacies 
Governments oversee the pharmaceutical manufacturing process by 
setting standards for quality controls and good manufacturing practices. The 
public employees who oversee these processes have conflicts of interest 
when they receive gifts or have other financial ties with these firms. 
National authorities typically inspect pharmaceutical manufacturing 
facilities. Governments oversee the process of distributing pharmaceuticals 
through controls on imports and rules for storage, transportation, and 
delivery. The public employees who oversee this process have conflicts of 
interest when they receive gifts or have other financial ties with the firms 
involved in the distribution process. National authorities also often inspect 
pharmacies and other pharmaceutical facilities. Inspectors with financial 
ties to the firms they regulate have conflicts of interest that compromise 
their work. 
 
Procurement 
Public authorities, private insurers, hospitals, and other parties often 
procure medicines. When choosing among various products and deciding 
what price to pay, these parties are supposed to act in the interest of the 
entities they serve. However, these individuals and organizations sometimes 
have financial ties with pharmaceutical firms or intermediary organizations; 
these relationships create conflicts of interest that can bias their 
procurement choices. 
 
Standard Treatment or Practice Guidelines 
 Standard treatment guidelines draw on existing medical knowledge 
to establish recommendations for good medical practice. These guidelines 
shape physician prescribing and clinical choices. In some countries (e.g., 
France) governmental authorities set practice guidelines. Other nations 
adapt WHO’s standard treatment guidelines (e.g., Ghana). In many other 
countries, medical specialty societies and insurers develop medical practice 
guidelines, including guidelines for medicine therapy. The professionals 
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who serve on committees that draft guidelines sometimes have financial ties 
to companies that can bias their decisions in drafting the guidelines. 
 
Formulary Selection Committees (by government, private insurers, and 
hospitals) 
 Hospitals and insurers typically develop formularies that restrict 
which pharmaceutical products physicians can prescribe or affect the co-
payments that patients pay. Individuals who serve on formulary committees 
and have financial ties with pharmaceutical firms have conflicts of interest 
that can bias the formulary choices. 
 
Continuing Professional Education Related to Pharmaceuticals 
 Continuing medical education (CME) shapes the knowledge and 
perceptions of professionals on clinical issues, including the appropriate use 
of pharmaceutical products. Organizations that develop CME programs and 
the CME speakers themselves can have conflicts of interest due to their 
reliance on grants from pharmaceutical firms to finance the program or 
from pharmaceutical firms paying for the CME speaker’s fees or from 
speakers and CME providers with other financial ties to drug firms. These 
conflicts can bias the information that physicians receive and influence their 
prescribing.  
In most countries, pharmaceutical firms play a major role in 
financing CME, often providing discretionary grants on topics they choose. 
They can thereby promote programs on topics related to their products. 
CME funders sometimes can also affect the choice of speakers at CME 
events and oversee the written materials used by speakers. This kind of 
pharmaceutical firm influence affects the content of materials presented. In 
some countries, drug firms also reimburse travel expenses of attending 
physicians; financial support that creates opportunities to influence 
physicians. 
 
Pharmaceutical Prescribing  
 In most countries, many pharmaceuticals are restricted to patients 
with a prescription from a designated professional. Physicians and other 
practitioners are supposed to prescribe medicines for the benefit of their 
patients. Yet, drug firms seek to influence prescribers. Drug firms often 
offer grants and gifts to prescribers or employ them as consultants to 
influence their prescribing choices. 
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Pharmaceutical Dispensing 
In some countries, physicians and other prescribers can also 
dispense medicines, own pharmacies, or have ties with pharmacies (or 
facilities that dispense medicines). When prescribers earn income from 
dispensing medicines or from having financial ties to organizations that 
dispense medicines, this creates a conflict of interest. Under those 
circumstances, the dispensing professional can increase his income by 
changing his prescribing choices. For example, the professional might 
prescribe more medicines than necessary, or select one medicine over 
another to boost his own income. 
 
Post-Marketing Drug Safety 
 Most countries rely on manufacturers to conduct post-marketing 
evaluation of their products and to report information on adverse reactions 
to national registration authorities. However, the incentives of 
manufacturers are often at odds with the interests of public safety. That 
conflict may cause them to invest insufficient resources to monitoring drug 
safety, to delay reports on adverse reactions and risks and to bias their 
analysis of risks.13 
 
 
 
III. STRATEGIES TO ADDRESS CONFLICTS OF INTEREST 
There are three main strategies used to address or cope with 
conflicts of interest (See Exhibit B: Conflicts of Interest: Intervention 
Points).14 For the purpose of illustration, we will assume the individual with 
a conflict of interest is a government employee or public servant. However, 
this also applies to other individuals who have conflicts of interest and are 
employed in the private sector. 
 
 
 
 
 
                                                
13 Marc A. Rodwin, Five Un-Easy Pieces of Pharmaceutical Policy Reform, 41 
J. L. MED. & ETHICS 581, 584-85 (2013). 
14 See The Future of Medicine, supra note 3, at 207. 
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Exhibit B 
Conflicts of Interest: Intervention Points 
 
 
PREVENTION 
-Before 
public servant acts 
 
REGULATION 
-During 
public servant acts 
SANCTIONS/RESTITUTION 
-After 
public servant acts 
Prohibit 
 
public servants 
from entering into 
situations with 
conflicts of interest 
 
Disclose 
conflicts of interest 
Supervise 
 
conduct of public 
servants and limit 
their discretion 
Penalize 
 
public servants for 
violations of trust 
 
 
Compensate 
those harmed if public servants 
abuse their trust 
 
 
The first strategy is to prevent the conflict of interest from occurring 
or to eliminate the conflict when it arises. This can be done by organizing 
the work of government authorities in ways that preclude key actors from 
entering into situations in which they would have a conflict of interest. 
Alternatively, when individuals have a conflict of interest, the individual or 
their employer can eliminate the conflict. 
The second strategy is to regulate the conduct of key actors who 
have conflicts of interest. This requires identifying key actors with conflicts 
of interest, then supervising their conduct. Overseeing the conduct of a 
conflicted actor can sometimes mitigate conflicts of interest. Reducing the 
discretion of key actors can decrease the risk that they will act in ways that 
are biased or breach their trust. Furthermore, if public authorities monitor 
the conduct of conflicted actors and suspect they have acted inappropriately, 
the authorities can overrule their decisions. 
The third strategy is to allow individuals to have conflicts of interest 
but to impose sanctions or provide restitution when public servants or 
publicly employed professionals have breached their duties. This approach 
assumes that the risk of being sanctioned will deter individuals from 
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breaching their obligations and that in any event, sanctions and restitution 
will provide adequate remedies when public employees breach their trust. 
The advantage of policies that preclude conflicts of interest from 
occurring is that this approach avoids the risks that conflicts of interest 
create. However, rules that preclude conflicts of interest usually restrict 
many activities, some of which are beneficial. For example, a rule that 
prohibits public employees from engaging in any outside remunerative 
activity will preclude many conflicts of interest. However, it might also 
preclude governmental employees from supplementing their income from 
activities that do not create conflicts of interest. A public employee in the 
pharmaceutical affairs department will not have conflicts of interest when 
she spends her weekends writing magazine articles on films and popular 
culture. 
A more nuanced approach is to eliminate conflicts of interest only 
after they arise. This approach restricts activities only when they are 
necessary to resolve the conflict. For example, an employee who reviews 
applications to market new medicines has a potential conflict of interest if 
they have a relative that works for Wonderpharma. When Wonderpharma 
submits an application to market a new medicine and the application is one 
the employee would normally review, the employee’s potential conflict of 
interest becomes an actual conflict of interest. The disadvantage of waiting 
until a conflict actually arises is that such strategy relies on the ability to 
identify the conflict and take appropriate action. However, such conflict of 
interest might not be identified if administrators cannot monitor the 
financial interests of employees and the manner in which their work 
activities might affect their financial interests. 
The advantage of employing policies that oversee conflicted actors 
is that these policies would not preclude potentially beneficial activities that 
might give rise to conflicts of interest. However, overseeing the activities of 
conflicted actors usually requires the use of significant resources, and it is 
difficult to properly execute. 
The advantage of policies that rely on sanctions and restitution is 
that they avoid preclusion of wide categories of activities as a preventive 
measure. It also avoids expending resources to monitor the conduct of 
conflicted actors. However, the disadvantage is that it is often difficult to 
identify breaches of trust, and sanctions often fail to provide an adequate 
remedy. Moreover, while sanctions can provide a remedy for breach of 
trust, they cannot provide remedies when the effect of a conflict of interest 
is biased governmental decisions. 
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IV. SIX STEPS PUBLIC MANAGERS SHOULD TAKE TO 
COPE WITH CONFLICTS OF INTEREST   
Step 1: Develop a Framework to Govern the Conduct of Public Employees 
and Private Sector Experts Who Advise the Government. 
The first step is to develop policies and a legal framework that will 
govern the conduct of public employees and elected or appointed public 
officials. Such rules should apply to all public employees, not only those 
whose work concerns pharmaceuticals. It is possible, however, to have 
distinct rules for employees working in ministries concerned with 
pharmaceuticals. 
Typically, after there is agreement on the basic policy, implementing 
the policy will require enacting legislation and/or the promulgation of 
administrative rules. These rules should set standards for the conduct of 
public employees and for private sector individuals who perform public 
functions, such as advising public officials or serving on government 
commissions. These rules can be part of civil service laws or separate laws 
that regulate the conduct of public employees and government officials. 
These rules should set standards for the conduct of employees and 
therefore include provisions that are broader than merely setting standards 
for conflicts of interest. These rules should include legal requirements and 
codes of conduct or ethics that supplement legal requirements. These rules 
should include anti-corruption measures (such as prohibitions on accepting 
or paying kickbacks or bribes or other breaches of public trust) and should 
specify prohibited activities because they are incompatible with certain 
public employment and public service. For example, the rules should 
restrict public employees from accepting gifts from parties affected by their 
work; they should also preclude employees from operating a business 
enterprise that contracts with the government. These rules might also 
prohibit public employees from exercising leadership positions in a political 
party or in an organization that seeks to change government policy on 
matters related to the employee’s work. 
Rules for public employment should restrict employees from 
participating in activities that create conflicts of interest. The rules should 
prohibit public officials from engaging in certain conduct and from having 
certain financial ties that create conflicts of interest. Other parts of this 
article provide examples of the kinds of activities that can be restricted (See 
Box 1: Sources of Conflicts of Interest for Public Employees). It is unlikely 
that public employment rules will preclude all conflicts of interest. 
Therefore, policies are needed to address conflicts of interest as they arise. 
Furthermore, rules are needed to govern the conduct of individuals 
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employed in the private sector who serve on governmental advisory boards 
or who perform other public functions. 
A public servant’s post-employment work can create conflicts of 
interest in three ways. First, public employees can provide favors to a 
regulated firm or to the industry more generally and in return receive a 
highly paid position in that industry after the employee leaves government 
service. An explicit offer of employment after leaving public office in 
return for a favor from a government official violates many public 
corruption laws. However, public officials do not have to make an explicit 
agreement; they might offer favorable treatment to pharmaceutical firms in 
expectation that the favor will be returned after they leave government 
service. Second, public officials often obtain confidential information that is 
valuable to the regulated industry and use that information to obtain 
lucrative post-public sector employment that relies on their knowledge of 
such confidential information. Third, public employees often develop 
personal relations with other officials, and a wide range of contacts with 
decision-makers. These employees can sometimes use these contacts and 
relationships after leaving government service to help regulated parties 
influence policy decisions. To address these problems many nations 
regulate certain activities of individuals after they leave public employment. 
 
Step 2: Develop Measures to Implement and Enforce Conflict of Interest 
Policy. 
Public authorities need a mechanism to implement conflict-of-
interest policies because they do not implement themselves. These 
mechanisms should include programs to educate and train public employees 
regarding legal standards, compliance, and how to resolve conflict-of-
interest problems. 
Policies that lack enforcement mechanisms have little value. There 
need to be public officials who are responsible for enforcing the conflict-of-
interest rules. If responsibility for overseeing conflicts of interest is 
delegated to government officials with numerous responsibilities, these 
officials will often focus their attention on other matters and neglect 
conflicts of interest. Therefore, it is preferable that the public officials 
charged with this task make implementing and enforcing conflict of interest 
policies their sole or primary responsibility. 
There must be consequences when government officials (or private 
sector actors who perform some other public function) violate conflict-of-
interest policies. First, there must be means to challenge and rescind 
governmental decisions when the responsible actors failed to comply with 
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conflict-of-interest rules. If a governmental commission included members 
who violated conflict of interest rules, then the decision of the commission 
should be deemed to lack legal authority. 
Disciplinary consequences are also required for public officials who 
fail to declare their financial interests or who report false information. 
These consequences can include negative employment evaluations, 
restrictions on promotions, removal from public employment or office, 
monetary fines, or criminal penalties. There also must be a means to 
discipline individuals employed in the private sector who violate conflict of 
interest rules when serving on governmental commissions or advisory 
boards. 
 
Step 3: Develop Measures to Promote Ethical Conduct and Voluntary 
Compliance. 
There should be codes of conduct and other measures to promote 
compliance with policies that require employees to report their personal 
financial interests and to avoid activities that are incompatible with their 
government position. Voluntary compliance is not a substitute for a system 
of legal and administrative rules to enforce these standards, but it is a useful 
supplement. An ethical culture is an important component in making 
conflict-of-interest policy effective because there are limits on what the law 
can achieve without most employees making good faith efforts to comply. 
For this reason, governmental authorities should create an 
organizational culture that promotes these values.15 As part of this effort, 
employers could develop codes of conduct or ethical codes for employees 
and train employees on how to comply. There also need to be laws that 
protect whistleblowers, individuals who report unlawful, dishonest, or 
corrupt governmental activity. Without such protection, many employees 
will be not report misconduct because they fear that powerful government 
officials will retaliate and jeopardize their careers. 
 
Step 4: Require Key Actors to Declare their Financial Interests. 
In order to manage conflicts of interest, it is necessary to identify 
them and that requires information about the work that public employees 
perform, their personal financial interests, and their activities outside of 
                                                
15 WHO, Good Governance for Medicines: A Model Framework (2014),  
http://apps.who.int/medicinedocs/documents/s21548en/s21548en.pdf. 
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their employment that can create conflicts of interest.16 Therefore, public 
policy should require that certain employees report to authorities on a 
regular basis, information on their financial interests, and activities that 
could conflict with their work duties. Bear in mind, disclosing financial 
interests does not eliminate or cure any conflict. Declarations of interest are 
not an end in themselves, but they are necessary to identify and manage 
conflicts of interest.17 
All public employees who exercise administrative, managerial, or 
policymaking responsibilities, or who perform professional roles, should 
report certain interests using a standard form. The forms should enumerate 
the specific categories of interests that employees must declare. These 
interests should include both the interests of the public employee and also 
those of their immediate family members.18 Individuals should file 
declarations of interest on an annual basis and, in addition, whenever they 
assume major new job responsibilities, or their personal financial interests 
undergo a significant change. (See Box 2: Declarations of Interests.) 
Governments should also require declarations of interest by private 
sector employees who serve on government commissions or advisory 
boards or who advise the government in other contexts. These individuals 
should complete declaration forms developed by public authorities that 
report the same information from public employees. 
Employees should disclose financial interests: income, gifts over a 
nominal value, investments, and ownership interests. Income should include 
money, in-kind benefits, and other items of economic value. Employees 
should also declare activities outside of government employment that could 
conflict with their work duties. These activities could include certain 
uncompensated working relationships such as serving on boards of 
corporations or not-for-profit organizations, and significant work for 
political parties.19 
Some conflict-of-interest policies only require employees to declare 
interests that directly relate to their employment duties or the activities of 
the ministry in which they work. The rationale is that interests not directly 
                                                
16 See, e.g., U.S. Department of Health and Human Services, Financial 
Disclosure by Clinical Investigators (February 2013), 
https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm341008.pdf. 
17 A Toolkit, supra note 3, at 27. 
18 18 U.S.C. § 208 (a) (2012). 
19 5 C.F.R. § 2635.502 (a)(2)(b)(1)(iv)-(v) (1992); 5 C.F.R. § 2635.502 
(a)(2)(b)(1)(iv)-(v) (2017). 
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related to an individual’s work duties are irrelevant and cannot create a 
conflict of interest. Such policies effectually reduce the information 
required to be disclosed and protect employee privacy. 
However, merely asking employees to decide whether a personal 
interest is relevant to their work entails risk. Employees often fail to see the 
relevance of a financial interest that is apparent to officials charged with 
overseeing conflicts of interest. Moreover, declarations of interests 
sometimes reveal a potential conflict of interest that can later become an 
actual conflict. Unless the potential conflict of interest is identified it cannot 
be managed. Most important, when individuals do not report personal 
interests because they consider them irrelevant, that precludes an objective 
review of whether a conflict of interest exists. Therefore, it is preferable to 
require declarations of all interests. It is the responsibility of governmental 
authorities, not the employee who files the declaration, to determine 
whether an employee has a conflict of interest, and how it should be 
managed. 
 
Step 5: Identify Individual and Institutional Conflicts of Interest. 
Individual Conflicts of Interest 
Designated officials need to analyze declarations of interest filed by 
employees in order to identify potential and actual conflicts of interest. The 
officials who review these declarations should be trained to identify 
conflicts of interest. These officials can include an attorney working in the 
government’s office of legal affairs, a compliance officer, or an official 
designated to oversee the ethics of governmental personnel. The reviewers 
should distinguish between financial interests that are related to the 
employee’s work and those that are not. Some governments prohibit all 
outside employment or remunerative activity while others allow employees 
to engage in certain limited outside employment (See Box 3: Analyzing 
Conflicts of Interest Check List).20 
Identifying conflicts of interest requires examining the individual’s 
work responsibilities in relation to their personal interests and outside 
activities. The first step is to identify the employee’s duties and the 
activities of the ministry in which the employee works. Employees can have 
                                                
20 5 U.S.C. § 502 (2011); Jack Maskell, Outside Employment, “Moonlighting,” 
by Federal Executive Branch Employees, CONGRESSIONAL RESEARCH SERVICE 
(December 12, 2012), https://fas.org/sgp/crs/misc/R42857.pdf. 
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conflicts of interest when they are involved in government decisions such as 
setting general policies, granting authorization to market pharmaceutical 
products, approving the conduct of pharmaceutical firms through inspection 
of manufacturing, or participating in the awarding of contracts and licenses 
or permits. Employees can also have conflicts of interest when they have 
access to confidential information. 
It is important to examine the scope of an employee’s duties. Certain 
high and middle-level employees can affect government policy on a wide 
range of matters. They might also be able to exercise power or influence 
over other employees. When these employees have conflicting outside 
interests, it can affect a broad scope of government activity. In contrast, 
other employees often have a narrowly defined scope of responsibility and 
authority and can affect governmental decisions only on limited matters. 
They have fewer opportunities for conflicts of interest than when an 
employee exercises broad authority. 
After identifying the kinds of decisions that the employee can 
influence, responsible officials should examine the employee’s declarations 
of interest to learn whether the employee has personal financial interests or 
engages in outside activities that might give rise to a conflict of interest. 
(See, Box 1: Sources of Conflicts of Interest for Public Employees.) 
Responsible officials should look at the individual’s: 1) Personal financial 
interests; 2) Financial interests and activities of family: including their 
spouse, betrothed, or individual with whom they cohabit; their parents; 
siblings and children; 3) Gifts; 4) Employment outside of public service; 5) 
Appointments outside of governmental work; 6) Employment after leaving 
government service. 
Declarations of interest can reveal financial ties arising from 
ownership and investment that can create conflicts of interest. Employees 
who earn income from ownership, investment, royalties, or patents related 
to pharmaceuticals cannot play a neutral role in making decisions related to 
the enterprises that generate that income. The issue that reviewers then need 
to ask is whether the employee participates in work that could affect those 
private enterprises and whether the employee’s interest in the private 
enterprise can affect their public employment activities. 
Declarations of interest might reveal that the employee has a conflict 
of interest arising from the interest of a family member of the employee. 
The public employee’s loyalty to their family might bias the public 
employee to favor the interests of a relative. 
Declarations of interest can also reveal that employees have received 
gifts or grants from businesses related to the employees’ work or from 
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individuals employed in those businesses. Some governments prohibit 
public employees from accepting any gifts. When public policy does not 
prohibit all gifts, they typically require their disclosure so responsible 
officials can respond appropriately. 
Most nations prohibit public employees from accepting gifts of any 
value from individuals or firms engaged in activities related to the 
employees’ work.21 However, some nations allow certain kinds of gifts or 
grants to support publicly employed physicians, researchers, or other 
employees. For example France allows pharmaceutical firms to pay for 
transportation and lodging for physicians to attend professional meetings 
and CME so long as the physician and pharmaceutical firm disclose the 
financing and they follow certain rules.22 Typically, the funds must be used 
to finance the cost of participating in professional activities, such as 
attending professional meetings or training, or to finance research. Some 
nations allow public employees to accept business hospitality, such as a 
meal, if the value falls below a certain threshold. 
Some governments prohibit public employees from engaging in any 
remunerated outside employment. When government employees are 
permitted to engage in limited outside employment, certain work can create 
conflicts of interest. For example, working part-time for a pharmaceutical 
firm will typically create a conflict of interest for employees in government 
ministries that oversee pharmaceutical policy. It could bias the employee to 
favor the pharmaceutical firm when he or she makes governmental 
decisions. In contrast, working part-time for an enterprise outside the 
pharmaceutical sector would typically be unrelated to the employee’s work 
and would not conflict. 
In some situations, it will be necessary to examine the outside 
employment closely to determine if there is a conflict of interest. When an 
employee works part-time for a law firm or consulting organization, that 
                                                
21 See Eric Raile, Managing Conflicts of Interest in The Americas: A 
Comparative Review, UNITED STATES OFFICE OF GOVERNMENT ETHICS (April 15, 
2004),  
https://www2.oge.gov/web/oge.nsf/0/63AFE8A872F928F285257EA6006557B4/$
FILE/36d75c57a708473ca786a10c264797783.pdf; OECD, Managing Conflict of 
Interest: Frameworks, Tools, and Instruments for Preventing, Detecting and 
Managing Conflict of Interest (2008), https://www.oecd.org/site/adboecdanti-
corruptioninitiative/40838870.pdf; The Future of Medicine, supra note 3, at 11-16. 
22 Marc A. Rodwin, Reforming Pharmaceutical Industry-Physician Financial 
Relationships: Lessons from the United States, France, and Japan, 39 J. L. MED. & 
ETHICS 662, 663 (2011). 
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work does not necessarily concern pharmaceutical matters related to the 
employee’s government employment. However, if the law or consulting 
work concerns pharmaceutical issues, then there might be a link. Reviewers 
need to probe which firms and types of businesses the law or consulting 
firms serves and the matters on which the employee worked. 
 Declarations of interest might also reveal certain unremunerated 
activities that create conflicts of interest. For example, a government 
employee who serves on the board of a firm or not-for-profit organization 
can develop relationships with those private sector entities that could lead 
the employee to favor that organization. This typically creates a conflict of 
interest if the ministry in which the employee works regulates the private 
sector organization with which the government employee is affiliated. 
 Responsible governmental authorities also need to review the post-
employment activities of certain government employees to determine if they 
comply with conflict of interest rules. These reviews are not, strictly 
speaking, a review of declarations of interest in the same sense as public 
employees. More often it will be a statement indicating the former 
employee’s current employment, their work responsibilities, and a 
statement that they have complied with rules on post-government 
employment. For example, governments often restrict employees for a 
designated number of years from representing any private sector actor in 
matters before the agency in which the former employee worked. 
Institutional Conflicts of Interest 
These are the five steps needed to identify an institutional conflict of 
interest: 1) Specify the organization’s mission and its activities; 2) List the 
organization’s financial interests and its source of funds (including all 
revenue, grants, royalties, and ownership interests; 3) List the 
organization’s affiliations with other organizations; 4) Review the 
institution’s mission, activities, financial interests, and affiliations to see if 
there are potential conflicts among them; 5) Finally, ask whether combining 
these activities could compromise performance of any one of them. Also 
ask whether the institution’s financial interests could bias the performance 
of its activities or pursuit of its mission. 
 
Step 6: Resolve or Manage Conflicts of Interest 
Assess the Significance of a Conflict of Interest 
Conflicts of interest are widespread; their potential impact is 
sometimes difficult to assess. Some are minor and can be ignored without 
much risk of harm. But there is no simple way to determine to what degree 
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a conflict of interest compromises an individual’s loyalty, judgment, and 
fulfillment of their obligations. In each case, we must review the facts and 
context to reach a conclusion. When a declaration of interests reveals a 
potential or actual conflict of interest, then officials have the responsibility 
to assess the significance of the conflict and decide what action to take. 
Some financial conflicts of interest are more serious than others. We 
can reasonably expect that the risk posed by compromising financial ties 
increases as the amount of money involved increases. As a practical matter, 
public policy often accepts the presence of certain small financial conflicts 
of interest in order to focus on more significant conflicts. However, research 
shows that even small gifts and financial ties often create feelings of 
gratitude and generate reciprocity.23 Hence, there are also grounds to restrict 
the existence of small ties. 
We need to ask several questions. How strong or direct are the 
conflicts? What is the probability of inappropriate behavior? What kinds of 
risk are posed? How serious might the consequences be? What effect would 
measures to eliminate or manage the conflict have on other goals? 
Some employees might play such an important role in decision-
making that it is prudent to manage even their potential conflicts of interest 
in order to avoid likely problems if an actual conflict of interest arises. 
However, not all potential and actual conflicts of interest are of the same 
importance. In some cases, the responsible official might conclude that the 
conflict of interest is so small that no action needs to be taken aside from 
disclosing the conflict in the name of transparency.  
When a significant conflict of interest arises, however, public 
officials need to take action to either resolve or manage the conflict. It is 
often tempting for responsible officials to assume that rules on conflicts of 
interest should be waived because the government employee or private 
sector expert is essential and there is no way to resolve or manage the 
conflict of interest. In most cases, this is not true. There should be few if 
any waivers of rules and when they occur, the basis for the decision should 
be justified in writing and made public. 
                                                
23 See Jason Dana & George Loewenstein, A Social Science Perspective on 
Gifts to Physicians from Industry, 290 J. AM. MED. ASSOC. 252, 254 (2003); 
Dennis T. Regan, Effects of a Favor and Liking on Compliance, 7 J. OF 
EXPERIMENTAL SOC. PSYCHOL. 627, 631 (1971); Hershey H. Friedman & Ahmed 
Rahman, Gifts-Upon-Entry and Appreciatory Comments: Reciprocity Effects in 
Retailing, 3 INT’L J. OF MARKETING STUD. 161, 163 (2011). 
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Resolve Individual Conflicts of interest 
Two main strategies can be employed to resolve a conflict of 
interest: A) change the compromised employee’s relationship to the private 
interest; B) change the compromised employee’s work activities. 
 
A) Change The Compromised Employee’s Relationship to the Private 
Interest 
• Divest the private ownership interest 
The employee can sell their ownership or investment interest in the private 
entity. Severing the financial ties eliminates the conflict of interest. 
• Terminate the relationship with the private entity.  
The employee can resign from the board or cease other relationships with 
the private entity in order to end the conflict. 
• Place the employee’s investment interests in a blind trust 
The employee’s stock or other investment can be placed in a blind trust 
managed by an independent party that has no contact with the public 
official. This will prevent the government official from controlling their 
investments while the official is in a position to make decisions that can 
affect those investments. The trustee has authority to manage the investment 
portfolio through sales and purchases but cannot consult with the public 
official. This option is typically used for high-level public officials who 
own stock in publicly traded firms. 
 
B) Change The Compromised Employee’s Work Activities  
• Resign: The official can end his public employment and thereby end 
the conflict. 
• Recusal: The public official can withdraw from participating in any 
governmental decisions that can affect her private financial 
interest.24 
• Reassign work duties: The employee’s duties can be changed so that 
the official does not work on activities that can affect her private 
                                                
24 Recusal are an effective tool when the conflict of interest will occur very 
infrequently. 
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interests. The employee can be reassigned to work in a different 
division or her work duties can be modified in other ways. 
• Restrict access to information: The government can limit the 
employee’s access to information that might be used to advance her 
private interests. Typically, when government officials work on 
general policy and regulatory matters it makes sense to preclude 
their conflicts of interest. The reason is that it is difficult to separate 
particular work activities and decisions that can affect the official’s 
private interests from work activities that do not. It is therefore not 
administratively feasible to cope with the conflict by restricting only 
discrete employment activities. Resolving the conflict requires 
severing the employee’s financial tie to the pharmaceutical firm or 
changing the employee’s work responsibilities. 
In contrast, when public employees do not work on general policy 
matters but work on making discrete decisions that only concern particular 
firms, it is often possible to distinguish potential from actual conflicts of 
interest. This makes it feasible to change the employee’s work 
responsibilities in order to preclude a potential conflict of interest from 
becoming an actual conflict of interest. 
Sometimes government policies restrict public employees who work 
in a regulatory capacity from having any financial ties with a regulated 
industry to preclude even potential conflicts of interest. Alternatively, 
governments could minimize restrictions and permit financial ties that 
create potential conflicts of interest if it is possible to separate the 
employee’s activities that can affect the firms with which they have a 
financial tie from activities that will not affect the firm. 
 
Resolve Institutional Conflicts of interest 
Institutional Conflicts of interest can be resolved in the following ways: 
• Change the intuition’s responsibilities to eliminate conflicting roles; 
• Terminate the institution’s financial ties that create a conflict of 
interest. 
 
Manage Conflicts of Interest 
 When it is not feasible to resolve conflicts of interest, they can be 
managed to reduce the risk of bias or misconduct. There are two main ways 
to do so. 
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1) Oversee the Work of Conflicted Public Employees 
One option is to oversee or supervise the conflicted employee to 
reduce the risk that the employee will abuse the public’s trust. The 
employee’s supervisor can check on her performance and modify her 
decisions if the employee acts inappropriately. It is worth noting that this 
kind of supervision is costly, burdensome, and difficult to do well. There is 
a significant risk that the planned oversight will be done ineffectively.25 
Furthermore, written plans for supervision can create the appearance that 
the conflict of interest is being effectively managed when in fact it is not. 
Supervision as a safeguard is used with varying degrees of success in two 
contexts outside of public employment. 
First, American universities oversee the conflicts of interest of 
clinical researchers who have financial interests in the research.26 The 
preferred practice is to bar individuals who have financial interests in a 
particular medicine or method of therapy from conducting research to 
evaluate the therapy. However, sometimes the university allows the 
individual to participate in the research subject to certain restrictions. For 
example, the conflicted researcher might be allowed to play a role in the 
research but not be allowed to direct the project. Alternatively, the 
university might set up a committee to monitor the research and data 
produced.27 If the conflict of interest can affect the enrollment of human 
research subjects the university might require the presence of a patient 
representative to monitor the process of enrolling research subjects and 
obtaining their consent. However, the effectiveness of these practices 
remains unevaluated and there is significant reason to believe that they 
often are not effective.28 
                                                
25 See Joel Lexchin & Orla O’Donovan, Prohibiting or Managing Conflict of 
Interest? A Review of Policies and Procedures in Three European Drug 
Regulation Agencies, 70 SOC. SCI. & MED. 643, 643-47 (2010). 
26 Marc A. Rodwin, Conflicts of Interest in Human Subject Research, HUMAN 
RESEARCH ETHICS AND THE DECLARATION OF HELSINKI (forthcoming 2019); 
Susan H. Ehringhaus et al., Responses of Medical Schools to Institutional Conflicts 
of Interest, 299 J. AM. MED. ASSOC. 665, 667 (2008). 
27 Bernard Lo & Marilyn J. Field, Conflict of Interest in Medical Research, 
Education, and Practice, IOM (2009), 
http://www.kumc.edu/Documents/coi/TOC.pdf. 
28 See Id.; Leslie Z. Benet, Presentation to the Institute of Medicine Committee 
on Conflict of Interest in Medical Research, Education, and Practice: Perspectives 
on Financial Relationships and Conflicts of Interest in Basic and Early Stage 
Translational Research: Reflections on 28 years of Organized COI Experience at 
UCSF (May 22, 2008). 
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A second example of managing conflicts of interest arises in the 
case of American insurers. Physicians paid fee-for-service often have a 
conflict of interest because they have a financial incentive to prescribe the 
services that they provide. In response to this common situation, American 
insurers created or adopted practice guidelines. The health insurers then 
appoint utilization reviewers to determine whether physicians have 
prescribed services or medications that do not conform to practice 
guidelines. The insurers typically have the authority to overrule the clinical 
choices of these physicians or to refuse payment for services deemed 
medically unnecessary according to medical practice guidelines.29 
The system of utilization review by private health insurers described 
above is rarely used outside the United States. Instead, many countries have 
adopted WHO standard treatment guidelines for therapeutic use of 
medications.30 Many nations use these standard treatment guidelines to 
restrict the use of medications through pharmaceutical formularies in public 
hospitals and national health insurance systems. 
 
2) Minimize the Role of Conflicted Actors 
If a conflicted individual participates in a group that makes a 
decision, the conflicted individual’s influence decreases as the number of 
people who participate in the decision increases. Consider, for example, a 
conflicted expert who serves on a commission to recommend whether to 
approve marketing of a medicine. The conflicted expert’s vote will have 
greater weight if five rather than twelve individuals serve on the 
commission. Reducing the number of conflicted experts that serve on a 
commission decreases the risk that bias will determine the results. 
Nevertheless, the conflicted expert can also influence the outcome by 
convincing others who serve on the commission to adopt her point of view, 
so conflicted individuals have more influence than their vote alone.  
                                                
29 Marc A. Rodwin, Conflicts in Managed Care, 332  NEW ENG. J. MED. 604, 
604-05 (1995);  See Marc A. Rodwin, Physicians' Conflicts of Interest in HMOs 
and Hospitals, CONFLICTS OF INTEREST IN CLINICAL PRACTICE AND RESEARCH 
197, 198 (1996).  
30 See, e.g., Standard Treatment Guidelines and Essential Medicines Lists, at 
http://siapsprogram.org/approach/pharmaceutical-services/essential-medicines-
lists/; 
 See generally WHO, The Selection and Use of Essential Medicines: Report of 
the WHO Expert Committee (2015), http://apps.who.int/medicinedocs/documents/
s22190en/s22190en.pdf. 
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Manage Institutional Conflicts of Interest 
Institutional conflicts of interest are more difficult to manage than 
individual conflicts of interest because organizational leaders often have 
their own professional interests aligned with the institution’s short-run 
interests. They are therefore likely to find it challenging to take actions that 
restrict organizational activities that create the institutional conflicts of 
interest. Institutional leaders can try to address this problem by appointing 
managers without conflicts of interest to manage the institution’s conflicts 
of interest. They may employ the following strategies: 
• Create firewalls that separate the functions of different parts of the 
organization that have conflicting functions or financial interests; 
• Limit contact between individuals who work in different divisions of 
the organizations that have conflicting interests and financial 
interests. 
 
CONCLUSION  
This article outlined twelve areas in which conflicts of interest 
compromise pharmaceutical policy and practice and six steps policymakers 
should take to identify, eliminate, or manage such conflicts.  Many conflicts 
of interest can be eliminated or managed when they are identified.  
However, effectively coping with conflicts of interest requires the existence 
of a legal framework, institutions to oversee conflicts of interest, a clear 
strategy, and resources to implement these public policies. 
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Appendix: 
Conflicts of Expert Advisors in the Private Sector 
 
Frequently, governments seek the help of experts who are not public 
employees to advise them on various issues, including: 1) whether to 
approve the registration, marketing, and sale of a new pharmaceutical 
product (and if so on what terms); 2) whether to add a pharmaceutical 
product to a list of essential medicines or a formulary list that determines 
which medicines will be available at public hospitals and clinics; or 3) the 
level of reimbursement the government should pay for purchase of a 
pharmaceutical product. The government will often appoint these 
individuals to serve on governmental commissions or advisory boards. 
When these individuals advise the government, they perform a public 
function and are supposed to act on behalf of the public. However, because 
they work in the private sector, they might have financial ties with 
pharmaceutical firms that create a conflict of interest. These financial ties 
can include employment or consulting with a pharmaceutical firm, receipt 
of research grants, or gifts from a pharmaceutical firm or from a foundation 
affiliated with a pharmaceutical firm. 
To avoid conflicts of interest, rules should restrict who can serve on 
advisory boards. The rules should exclude employees of a firm that 
manufactures, sells or markets pharmaceutical products as well as 
individuals who have financial ties with a firm whose products might be 
affected by decisions of the advisory board. 
When a government advisory board meets to determine whether a 
firm should be allowed to market a new medicine, the board should not 
include any former employee of that firm. Similarly, the board most likely 
should not include any individual who has worked for a firm that markets a 
medicine or that competes with the firm seeking to market the new 
medicine. When developing a list of products to be included in a medicine 
formulary or list of essential medicines, the government commission should 
not include experts who have worked for a firm whose products might be 
included on the list. When a commission makes recommendations on 
reimbursement for the sale of a medicine, the best practice is for the 
commission to exclude individuals who have worked for the firm that 
manufactures that product, or who have worked on a competing medicine. 
Government officials sometimes seek to waive rules that exclude 
conflicted actors because the actors have special qualifications that are 
difficult to find and because they believe the conflict of interest is small and 
will not have any effect on the actor’s conduct. Certainly, having a large 
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financial interest in a matter presents a greater risk than a small one. 
Therefore, it often makes sense to establish a financial threshold below 
which income from a pharmaceutical firm will not preclude an expert 
serving on a commission. Likewise, rules might ignore financial ties from 
work many years in the past on the grounds that they will not have any 
effect on the individual’s conduct. 
Nevertheless, studies on the effects of gifts and other financial 
incentives reveal that they can create bias even when they are small. 
Furthermore, individuals with an existing working relationship with a 
pharmaceutical firm (even if the work only generated modest revenue and 
occurred several years ago) might want to avoid taking action that could 
damage that relationship and jeopardize future consulting income. 
Therefore, it is preferable to bar individuals with conflicts unless there is no 
alternative. 
Sometimes administrators believe that they cannot find individuals 
without conflicts of interest to advise them. This is rarely, if ever, true. For 
example, the kind of expertise needed to serve on an advisory board that 
evaluates whether to approve the marketing of a new medicine, does not 
require expertise in the medicine or the disease it treats, although that might 
be helpful. Typically, what is required is the ability to evaluate medical 
studies and literature, and to critically evaluate claims of the medicine 
sponsor. Many more individuals will have that expertise than specialized 
knowledge in a particular medicine or illness. Furthermore, if unconflicted 
experts do not reside in the locality, it is possible to engage the services of 
an expert who lives outside the nation. 
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BOX 1: CONFLICTS OF INTEREST OF PUBLIC EMPLOYEES 
1) Personal Financial Interests, Investment and Ownership Interests  
• The employee’s investment and ownership interest or other 
financial interests that conflict with work duties can be a source 
of conflicts of interest. There is a risk that an official who invests 
in or owns an entity that can be affected by her work will use her 
work position to favor their investment interest. 
2) Family Members’ Financial Interests And Activities 
• The employee’s family members’ financial interests and 
affiliations can be a source of conflicts of interest. 
3) Gifts and other Benefits from Private Interests 
• Public officials who receive gifts, grants, favors, or other benefits 
from private entities might act to help those private entities. 
4) Supplemental Private Employment 
• Sometimes the law allows public employees to engage in part-time 
employment or other remunerative activity in the private sector. 
Some of these private remunerative activities can interfere in the 
official’s performance of her public duties. 
5) Private Sector Appointment and Performing Unpaid Work for 
Private Entities 
• Public officials might serve on a board or advise a private entity 
without compensation on matters that concern their work activity. 
There is a risk that the officials will use their access to government 
information to favor one entity over another or that in performing 
their public duties the public official will favor the entity with which 
they have an affiliation. 
6) Post-Governmental Employment 
• Employment after leaving government service can create a conflict 
of interest in two ways. First, while working in the public sector, the 
official might try to secure a job in the private sector by granting 
special favors to a regulated firm. Second, after leaving public 
service, the public official might use confidential information 
obtained while publicly employed to benefit the private firm. 
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BOX 2: DECLARATIONS OF INTERESTS 
 
The declaration forms should ask employees to disclose for themselves and 
their family the following interests. The employee answer should indicate 
the purpose of the private entity and its activities. The form should specify 
any activities that are related to the employee’s work, namely work on 
pharmaceutical matters.  
 
Ownership and Investment Interests 
• Real estate (excluding family home) 
• Ownership or shares in private companies (sole proprietorships, 
partnerships, limited partnerships, stock ownership, other 
investments interests) 
• Patents 
Income generated through work or contracts with firms in private sector 
• Part-time employment 
• Consulting 
• Royalties 
• Corporate distributions 
• Serving on boards 
• Honoraria  
• Fees for speaking 
• Contracts that have generated or can generate other income 
Loans from entities other than banks, credit unions 
• Loans from private firms 
Gifts from firms or individuals employed by a business related to the 
employee’s work 
• Cash 
• Goods or objects worth more than $20 
• Meals worth more than $20 
• Transportation provided by private entities or travel expenses 
reimbursed greater than $20 
• Other business hospitality and entertainment 
Affiliations with Firms and Not-For-Profit Organizations 
• Directorships 
• Appointments 
• Leadership positions 
Family Members (Spouse or domestic partner, parents, siblings, children) 
• Employment or business activity of immediate family members. For 
purposes of disclosure, family members should include individuals 
to whom they are betrothed or with whom they cohabit. 
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BOX 3: A CHECK LIST TO ANALYZE CONFLICTS OF INTEREST 
 
I) Is there a conflict of interest? 
 
1) Who is the actor and what is his/her designated role? 
2) To whom does the actor owe a legal or ethical duty? 
3) What is the nature of that duty or obligation? 
4) Does the actor have a financial tie, a secondary activity or a 
secondary role that creates a risk that the actor will not fulfill her 
duty? 
5) When the actor exercises professional discretion, can the actor 
promote his/her own financial interest or the financial interest of a 
third party? 
 
II) How significant is the conflict of interest? 
 
1) Is the financial incentive for the actor so strong that it may cause 
him to behave in ways that promote his/ her own self-interest or 
that of a third party? 
2) How much discretion does the actor have in making professional 
decisions? 
3) What are the potential risks/ harms that can result if the actor is 
biased in exercising his/ her discretion or the actor violates his/ 
her duties? 
 
III) What policy options exist to eliminate, mitigate, or help 
manage the conflict of interest? 
 
Consider at least these kinds of options: 
1) Changes in the organization and financing of medical care; 
2) Separation of professional roles or activities; 
3) Restrictions on having certain financial ties or relationships; 
4) Oversight of professional activity to reduce discretion or monitor 
performance; 
5) Disclosure of financial ties to allow patients and other parties to 
protect themselves or to facilitate monitoring and management of 
professionals with CI; 
6) Remedies after a breach of duties (such as restitution to individuals 
harmed an penalties for individuals who violate their duties). 
